Investigational drug · Phase 3
MRI contrast-enhancing agents
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Sclerosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "MRI contrast-enhancing agents"
First trial start
2023
Dec 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRI contrast-enhancing agents", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MRI contrast-enhancing agents" as an intervention, largest first.
- A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisPivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07930624 · 2,500 participants (planned) · Start Feb 15, 2027 · Primary completion May 16, 2031
Drug: Frexalimab; Frexalimab and 6 more · For: Multiple Sclerosis
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06141473 · 1,655 participants · Start Dec 13, 2023 · Primary completion May 6, 2027
Drug: Frexalimab; Teriflunomide and 5 more · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Homewood, Alabama · 382 sites in all
- Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06141486 · 943 participants · Start Dec 27, 2023 · Primary completion Mar 24, 2028
Drug: Frexalimab; Placebo and 1 more · For: Multiple Sclerosis
Sites: Homewood, Alabama; Scottsdale, Arizona; Berkeley, California · 311 sites in all
- ImmunoMRI for Assessment of Tumor-associated MacrophagesNot yet recruiting
Medical University of ViennaAcademic, hospital or other
NCT07066436 · 60 participants (planned) · Start Oct 2025 · Primary completion Mar 2028
Drug: MRI contrast-enhancing agents · For: DLBCL - Diffuse Large B Cell Lymphoma
Sites: Vienna, Austria
Newest research
PubMed records naming it or its code names, newest first.
- Coating influence on inner shell water exchange: An underinvestigated major contributor to SPIONs relaxation properties.
Peng Y, Li Y, Li L, et al. · Nanomedicine 2023
- Hyaluronic acid (HA)-Gd(III) and HA-Fe(III) microgels as MRI contrast enhancing agents.
Sahiner N, Umut E, Suner SS, et al. · Carbohydr Polym 2022
- Nanotechnology and MRI contrast enhancement.
Matson ML, Wilson LJ · Future Med Chem 2010
- Gadofullerene MRI contrast agents.
Bolskar RD · Nanomedicine (Lond) 2008
- Gadolinium(III) di- and tetrachelates designed for in vivo noncovalent complexation with plasma proteins: a novel molecular design for blood pool MRI contrast enhancing agents.
Martin VV, Ralston WH, Hynes MR, et al. · Bioconjug Chem 1995
- Interactions of nitroxides with plasma and blood: effect on 1/T1 of water protons.
Bennett HF, Brown RD, Keana JF, et al. · Magn Reson Med 1990
Also in development for Multiple Sclerosis
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
- IMU-838Vidofludimus calciumPhase 33 trials
Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- MRI contrast-enhancing preparationsPhase 32 trials
Sanofi · Multiple Sclerosis
- zamtocabtagene autoleucelMB-CART2019.1Phase 25 trials
Miltenyi Biomedicine GmbH · CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
- Autologous HB-adMSCsPhase 22 trials
Hope Biosciences LLC · Traumatic Brain Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.